Caricamento...
Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy
BACKGROUND AND PURPOSE: Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. METHODS: Eighty-five patients received perampane...
Salvato in:
| Pubblicato in: | J Clin Neurol |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Korean Neurological Association
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6031997/ https://ncbi.nlm.nih.gov/pubmed/29971974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3988/jcn.2018.14.3.296 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|